摘要
目的:探讨阿托伐他汀联合非诺贝特防治缺血性脑卒中的临床效果及对患者治疗前后血脂、高敏C反应蛋白(hs-CRP)的影响。方法:64例缺血性脑卒中患者随机分为观察组与对照组各32例。两组患者均给予常规对症治疗,同时对照组给予阿托伐他汀片20 mg,po qn;观察组在对照组基础上再加用非诺贝特胶囊0.2 g,po qd。两组疗程均为3个月。比较两组患者治疗前后神经功能缺损评分、血脂和血清hs-CRP水平变化,及两组药品不良反应。随访1年,观察两组患者脑卒中复发情况。结果:治疗后两组CNDF评分均较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗后观察组血脂、血清hs-CRP水平较治疗前明显改善(P<0.05),且均明显优于对照组(P<0.05);而对照组治疗前后血脂、血清hs-CRP水平差异无统计学意义(P>0.05)。两组不良反应发生率差异无统计学意义(P<0.05)。对照组复发率明显高于观察组(P<0.05)。结论:阿托伐他汀联合非诺贝特治疗缺血性脑卒中效果显著,可有效调节血脂、降低血清hs-CRP水平和不良脑血管事件的复发,值得临床推广使用。
Objective： To discuss the clinical effect of atorvastatin combined with fenofibrate on the treatment of ischemic stroke and its influence on blood lipid,high-sensitivity C-reactive protein（ hs-CRP） level. Methods： 64 cases of ischemic stroke were divided into observation group and control group at random,two groups of patients were given routine symptomatic treatment,control group（ 32 patients） was given atorvastatin tablet 20 mg,po qn,treatment for 3 months; the treatment group（ 32 cases） was given fenofibrate capsule 0. 2 g,po qd based on the control group,treatment for 3 months.The nervefunction deficit score,blood lipid,hs-CRP level before and after treatment the two groups,and the adverse reactions of the two groups were compared. In one year follow-up,the recurrence rate of two groups were observed. Results： after treatment,the CNDF score of two groups were significantly decreased,the score of treatment group was significantly lower than the control group（ P〈0. 05）. After treatment,the blood lipid and serum hs-CRP levels of observation group were all improved significantly than before（ P〈0. 05）,and were much better than that of the control group（ P〈0. 05）,but there were no significantly difference on the serum hs-CRP level and blood lipid of control group（ P〈0. 05）. The incidence rate of adverse reaction of the two groups had no statistically significant（ P〈0. 05）. After one year of follow-up,the recurrence rate of control group was much higher than that of the observation group（ P〈0. 05）. Conclusion： The effect of atorvastatin combined with fenofibrate for ischemic stroke is significantly,can effectively regulate blood lipid,reduce the serum hs-CRP levels and adverse cerebrovascular event recurrence,is worth promoting in clinical use.
出处
《药物流行病学杂志》
CAS
2015年第4期207-209,215,共4页
Chinese Journal of Pharmacoepidemiology
